AS OF NOVEMBER 2008, WE HAVE RELOCATED OUR HEADQUARTERS.  PLEASE SEE THE CONTACT US PAGE FOR OUR NEW CONTACT INFORMATION.

On June 14, 2007 the NASD approved Tetragenex Pharmaceuticals, Inc. to be quoted on the NASDAQ Bulletin Board under the symbol TTRX.

Click HERE to read the June 2007 Chairman's letter to the shareholders.

Tetragenex Pharmaceuticals Inc. (formerly Innapharma, Inc.) is a publicly held biopharmaceutical company working to discover, develop and commercialize proprietary pharmaceutical products that treat serious diseases for which current therapies are inadequate. We have synthesized and patented a novel platform of pharmaceutical “small chain” peptides that treat depression, and may treat anxiety and other central nervous system disorders. Our leading product candidate is the antidepressant compound nemifitide, is in advanced, late Phase II, human clinical trials.

The Company, has also synthesized and is developing a platform of new and unique chemically-modified tetracycline molecules to be used in the treatment of certain types of cancer and antibiotic-resistant bacterial infections. These tetracycline-based product candidates are in the pre-clinical development stage.

Our objective is to license our platform of CNS compounds to a pharmaceutical company that is capable of completing the development and eventually distributing these compounds once they are registered.  As we proceed on this front we will continue the expansion of our clinical program. 

We intend to expand our scientific staff and attempt to become a fully integrated pharmaceutical company, primarily through our expertise in the identification, acquisition, and development of pharmaceutical products and technologies.